NEUROCRINE BIOSCIENCES INC Operating Income
NEUROCRINE BIOSCIENCES INC (NBIX) reported Operating Income of $151.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC operating income (loss) for the quarter ending 2026-06-30 was $151.50M, a 4.05% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating income (loss) for the quarter ending 2026-03-31 was $193.40M, a 719.49% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating income (loss) for the quarter ending 2025-12-31 was $210.90M, a 48.52% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating income (loss) for the quarter ending 2025-09-30 was $239.00M, a 30.03% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating income (loss) for fiscal 2025 was $619.10M, a 8.52% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC operating income (loss) for fiscal 2024 was $570.50M, a 127.38% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC operating income (loss) for fiscal 2023 was $250.90M, a 0.76% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC operating income (loss) for fiscal 2022 was $249.00M, a 142.93% increase from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $151.50M 10-Q · filed 2026-07-31 | $344.90M 10-Q · filed 2026-07-31 | $555.80M derived: sum of 3 quarters · filed 2026-07-31 | $794.80M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $193.40M 10-Q · filed 2026-05-05 | $404.30M derived: sum of 2 quarters · filed 2026-05-05 | $643.30M derived: sum of 3 quarters · filed 2026-05-05 | $788.90M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $210.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $449.90M derived: sum of 2 quarters · filed 2026-02-11 | $595.50M derived: sum of 3 quarters · filed 2026-07-31 | $619.10M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $239.00M 10-Q · filed 2025-10-28 | $384.60M derived: sum of 2 quarters · filed 2026-07-31 | $408.20M 10-Q · filed 2025-10-28 | $550.20M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $145.60M 10-Q · filed 2026-07-31 | $169.20M 10-Q · filed 2026-07-31 | $311.20M derived: sum of 3 quarters · filed 2026-07-31 | $495.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $23.60M 10-Q · filed 2026-05-05 | $165.60M derived: sum of 2 quarters · filed 2026-05-05 | $349.40M derived: sum of 3 quarters · filed 2026-05-05 | $494.80M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $142.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $325.80M derived: sum of 2 quarters · filed 2026-02-11 | $471.20M derived: sum of 3 quarters · filed 2026-02-11 | $570.50M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $183.80M 10-Q · filed 2025-10-28 | $329.20M derived: sum of 2 quarters · filed 2025-10-28 | $428.50M 10-Q · filed 2025-10-28 | $578.80M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $145.40M 10-Q · filed 2025-07-30 | $244.70M 10-Q · filed 2025-07-30 | $395.00M derived: sum of 3 quarters · filed 2026-02-11 | $536.20M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $99.30M 10-Q · filed 2025-05-05 | $249.60M derived: sum of 2 quarters · filed 2026-02-11 | $390.80M derived: sum of 3 quarters · filed 2026-02-11 | $464.40M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $150.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $291.50M derived: sum of 2 quarters · filed 2026-02-11 | $365.10M derived: sum of 3 quarters · filed 2026-02-11 | $250.90M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $141.20M 10-Q · filed 2024-10-30 | $214.80M derived: sum of 2 quarters · filed 2024-10-30 | $100.60M 10-Q · filed 2024-10-30 | $204.00M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-06-30 | $73.60M 10-Q · filed 2024-08-01 | -$40.60M 10-Q · filed 2024-08-01 | $62.80M derived: sum of 3 quarters · filed 2025-02-10 | $150.60M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-03-31 | -$114.20M 10-Q · filed 2024-05-01 | -$10.80M derived: sum of 2 quarters · filed 2025-02-10 | $77.00M derived: sum of 3 quarters · filed 2025-02-10 | $131.70M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2022-12-31 | $103.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $191.20M derived: sum of 2 quarters · filed 2025-02-10 | $245.90M derived: sum of 3 quarters · filed 2025-02-10 | $249.00M 10-K · filed 2025-02-10 | ||||
| 2022-09-30 | $87.80M 10-Q · filed 2023-10-31 | $142.50M derived: sum of 2 quarters · filed 2023-10-31 | $145.60M 10-Q · filed 2023-10-31 | $109.30M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-06-30 | $54.70M 10-Q · filed 2023-08-01 | $57.80M 10-Q · filed 2023-08-01 | $21.50M derived: sum of 3 quarters · filed 2024-02-09 | $66.00M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-03-31 | $3.10M 10-Q · filed 2023-05-03 | -$33.20M derived: sum of 2 quarters · filed 2024-02-09 | $11.30M derived: sum of 3 quarters · filed 2024-02-09 | $74.10M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2021-12-31 | -$36.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $8.20M derived: sum of 2 quarters · filed 2024-02-09 | $71.00M derived: sum of 3 quarters · filed 2024-02-09 | $102.50M 10-K · filed 2024-02-09 | ||||
| 2021-09-30 | $44.50M 10-Q · filed 2022-11-01 | $107.30M derived: sum of 2 quarters · filed 2022-11-01 | $138.80M 10-Q · filed 2022-11-01 | $210.60M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-06-30 | $62.80M 10-Q · filed 2022-08-04 | $94.30M 10-Q · filed 2022-08-04 | $166.10M derived: sum of 3 quarters · filed 2023-02-09 | $121.80M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-03-31 | $31.50M 10-Q · filed 2022-05-04 | $103.30M derived: sum of 2 quarters · filed 2023-02-09 | $59.00M derived: sum of 3 quarters · filed 2023-02-09 | $135.60M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2020-12-31 | $71.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $27.50M derived: sum of 2 quarters · filed 2023-02-09 | $104.10M derived: sum of 3 quarters · filed 2023-02-09 | $163.00M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | -$44.30M 10-Q · filed 2021-11-01 | $32.30M derived: sum of 2 quarters · filed 2021-11-01 | $91.20M 10-Q · filed 2021-11-01 | $140.00M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-06-30 | $76.60M 10-Q · filed 2021-08-03 | $135.50M 10-Q · filed 2021-08-03 | $184.30M derived: sum of 3 quarters · filed 2022-02-11 | $274.40M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-03-31 | $58.90M 10-Q · filed 2021-05-05 | $107.70M derived: sum of 2 quarters · filed 2022-02-11 | $197.80M derived: sum of 3 quarters · filed 2022-02-11 | $232.20M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2019-12-31 | $48.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $138.90M derived: sum of 2 quarters · filed 2022-02-11 | $173.30M derived: sum of 3 quarters · filed 2022-02-11 | $72.30M 10-K · filed 2022-02-11 | $72.28M 10-K · filed 2020-02-07 | |||
| 2019-09-30 | $90.10M 10-Q · filed 2020-11-09 | $90.10M 10-Q · filed 2019-11-04 | $124.50M derived: sum of 2 quarters · filed 2020-11-09 | $23.50M 10-Q · filed 2020-11-09 | $23.56M 10-Q · filed 2019-11-04 | $45.28M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2019-06-30 | $34.40M 10-Q · filed 2020-08-03 | $34.46M 10-Q · filed 2019-07-29 | -$66.60M 10-Q · filed 2020-08-03 | -$66.54M 10-Q · filed 2019-07-29 | -$44.82M derived: sum of 3 quarters · filed 2021-02-05 | $9.50M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2019-03-31 | -$101.00M 10-Q · filed 2020-05-06 | -$101.00M 10-Q · filed 2019-04-29 | -$79.22M derived: sum of 2 quarters · filed 2021-02-05 | -$24.90M derived: sum of 3 quarters · filed 2021-02-05 | -$26.75M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2018-12-31 | $21.78M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $76.10M derived: sum of 2 quarters · filed 2021-02-05 | $74.25M derived: sum of 3 quarters · filed 2021-02-05 | $36.80M 10-K · filed 2021-02-05 | $36.90M 10-K · filed 2019-02-08 | |||
| 2018-09-30 | $54.32M 10-Q · filed 2019-11-04 | $52.47M derived: sum of 2 quarters · filed 2019-11-04 | $15.02M 10-Q · filed 2019-11-04 | $26.86M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-06-30 | -$1.85M 10-Q · filed 2019-07-29 | -$39.30M 10-Q · filed 2019-07-29 | -$27.46M derived: sum of 3 quarters · filed 2020-02-07 | -$33.46M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-03-31 | -$37.45M 10-Q · filed 2019-04-29 | -$25.61M derived: sum of 2 quarters · filed 2020-02-07 | -$31.61M derived: sum of 3 quarters · filed 2020-02-07 | -$88.88M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2017-12-31 | $11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $5.84M derived: sum of 2 quarters · filed 2020-02-07 | -$51.43M derived: sum of 3 quarters · filed 2020-02-07 | -$131.36M 10-K · filed 2020-02-07 | ||||
| 2017-09-30 | -$6.00M 10-Q · filed 2018-11-05 | -$63.26M derived: sum of 2 quarters · filed 2018-11-05 | -$143.19M 10-Q · filed 2018-11-05 | -$189.45M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-06-30 | -$57.27M 10-Q · filed 2018-07-31 | -$137.20M 10-Q · filed 2018-07-31 | -$183.45M derived: sum of 3 quarters · filed 2019-02-08 | -$221.89M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-03-31 | -$79.93M 10-Q · filed 2018-04-30 | -$126.18M derived: sum of 2 quarters · filed 2019-02-08 | -$164.62M derived: sum of 3 quarters · filed 2019-02-08 | -$206.45M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2016-12-31 | -$46.25M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | -$84.69M derived: sum of 2 quarters · filed 2019-02-08 | -$126.52M derived: sum of 3 quarters · filed 2019-02-08 | -$147.37M 10-K · filed 2019-02-08 | ||||
| 2016-09-30 | -$38.44M 10-Q · filed 2017-11-01 | -$80.26M derived: sum of 2 quarters · filed 2017-11-01 | -$101.12M 10-Q · filed 2017-11-01 | -$131.87M derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-06-30 | -$41.83M 10-Q · filed 2017-08-03 | -$62.69M 10-Q · filed 2017-08-03 | -$93.43M derived: sum of 3 quarters · filed 2018-02-13 | -$129.28M derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-03-31 | -$20.86M 10-Q · filed 2017-05-09 | -$51.60M derived: sum of 2 quarters · filed 2018-02-13 | -$87.45M derived: sum of 3 quarters · filed 2018-02-13 | -$112.77M derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2015-12-31 | -$30.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$66.59M derived: sum of 2 quarters · filed 2018-02-13 | -$91.91M derived: sum of 3 quarters · filed 2018-02-13 | -$94.20M 10-K · filed 2018-02-13 | ||||
| 2015-09-30 | -$35.84M 10-Q · filed 2016-11-02 | -$61.17M derived: sum of 2 quarters · filed 2016-11-02 | -$63.45M 10-Q · filed 2016-11-02 | -$83.92M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-06-30 | -$25.32M 10-Q · filed 2016-08-03 | -$27.61M 10-Q · filed 2016-08-03 | -$48.08M derived: sum of 3 quarters · filed 2017-02-14 | -$64.94M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-03-31 | -$2.29M 10-Q · filed 2016-05-05 | -$22.76M derived: sum of 2 quarters · filed 2017-02-14 | -$39.61M derived: sum of 3 quarters · filed 2017-02-14 | -$53.97M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2014-12-31 | -$20.47M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | -$37.33M derived: sum of 2 quarters · filed 2017-02-14 | -$51.69M derived: sum of 3 quarters · filed 2017-02-14 | -$64.41M 10-K · filed 2017-02-14 | ||||
| 2014-09-30 | -$16.86M 10-Q · filed 2015-10-29 | -$31.22M derived: sum of 2 quarters · filed 2015-10-29 | -$43.94M 10-Q · filed 2015-10-29 | -$55.47M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-06-30 | -$14.36M 10-Q · filed 2015-07-29 | -$27.09M 10-Q · filed 2015-07-29 | -$38.62M derived: sum of 3 quarters · filed 2016-02-11 | -$50.62M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-03-31 | -$12.72M 10-Q · filed 2015-04-30 | -$24.25M derived: sum of 2 quarters · filed 2016-02-11 | -$36.26M derived: sum of 3 quarters · filed 2016-02-11 | -$49.43M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | -$11.53M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | -$23.54M derived: sum of 2 quarters · filed 2016-02-11 | -$36.70M derived: sum of 3 quarters · filed 2016-02-11 | -$49.68M 10-K · filed 2016-02-11 | ||||
| 2013-09-30 | -$12.01M 10-Q · filed 2014-11-04 | -$25.17M derived: sum of 2 quarters · filed 2014-11-04 | -$38.15M 10-Q · filed 2014-11-04 | -$29.57M derived: sum of 4 quarters · filed 2015-02-09 | ||||
| 2013-06-30 | -$13.17M 10-Q · filed 2014-08-06 | -$26.14M 10-Q · filed 2014-08-06 | -$17.56M derived: sum of 3 quarters · filed 2015-02-09 | -$21.52M derived: sum of 4 quarters · filed 2015-02-09 | ||||
| 2013-03-31 | -$12.97M 10-Q · filed 2014-05-01 | -$4.39M derived: sum of 2 quarters · filed 2015-02-09 | -$8.36M derived: sum of 3 quarters · filed 2015-02-09 | -$9.73M derived: sum of 4 quarters · filed 2015-02-09 | ||||
| 2012-12-31 | $8.58M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-09 | $4.62M derived: sum of 2 quarters · filed 2015-02-09 | $3.24M derived: sum of 3 quarters · filed 2015-02-09 | $1.45M 10-K · filed 2015-02-09 | ||||
| 2012-09-30 | -$3.96M 10-Q · filed 2013-10-29 | -$5.34M derived: sum of 2 quarters · filed 2013-10-29 | -$7.13M 10-Q · filed 2013-10-29 | -$6.69M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-06-30 | -$1.38M 10-Q · filed 2013-07-26 | -$3.17M 10-Q · filed 2013-07-26 | -$2.73M derived: sum of 3 quarters · filed 2014-02-11 | $27.71M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-03-31 | -$1.79M 10-Q · filed 2013-05-02 | -$1.34M derived: sum of 2 quarters · filed 2014-02-11 | $29.09M derived: sum of 3 quarters · filed 2014-02-11 | $30.19M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2011-12-31 | $447.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $30.89M derived: sum of 2 quarters · filed 2014-02-11 | $31.98M derived: sum of 3 quarters · filed 2014-02-11 | $33.92M 10-K · filed 2014-02-11 | ||||
| 2011-09-30 | $30.44M 10-Q · filed 2012-10-31 | $31.54M derived: sum of 2 quarters · filed 2012-10-31 | $33.48M 10-Q · filed 2012-10-31 | $33.35M derived: sum of 4 quarters · filed 2013-02-08 | ||||
| 2011-06-30 | $1.10M 10-Q · filed 2012-07-31 | $3.04M 10-Q · filed 2012-07-31 | $2.91M derived: sum of 3 quarters · filed 2013-02-08 | $5.37M derived: sum of 4 quarters · filed 2013-02-08 | ||||
| 2011-03-31 | $1.94M 10-Q · filed 2012-05-02 | $1.81M derived: sum of 2 quarters · filed 2013-02-08 | $4.28M derived: sum of 3 quarters · filed 2013-02-08 | -$1.61M derived: sum of 4 quarters · filed 2013-02-08 | ||||
| 2010-12-31 | -$129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $2.34M derived: sum of 2 quarters · filed 2013-02-08 | -$3.55M derived: sum of 3 quarters · filed 2013-02-08 | -$13.72M 10-K · filed 2013-02-08 | ||||
| 2010-09-30 | $2.47M 10-Q · filed 2011-10-31 | -$3.42M derived: sum of 2 quarters · filed 2011-10-31 | -$13.59M 10-Q · filed 2011-10-31 | |||||
| 2010-06-30 | -$5.89M 10-Q · filed 2011-07-29 | -$16.06M 10-Q · filed 2011-07-29 | ||||||
| 2009-12-31 | -$53.67M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |